Atossa Therapeutics, Inc.
ATOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $4 | $0 | $0 | $4 |
| Gross Profit | -$4 | $0 | $0 | -$4 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,370 | $5,502 | $4,157 | $3,403 |
| G&A Expenses | $0 | $3,538 | $3,257 | $3,748 |
| SG&A Expenses | $3,877 | $3,538 | $3,257 | $3,748 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$4 |
| Operating Expenses | $9,247 | $9,040 | $7,414 | $7,147 |
| Operating Income | -$9,251 | -$9,040 | -$7,414 | -$7,151 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $559 | $617 | $696 | $804 |
| Pre-Tax Income | -$8,692 | -$8,423 | -$6,718 | -$6,347 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,692 | -$8,423 | -$6,718 | -$6,347 |
| % Margin | – | – | – | – |
| EPS | -0.07 | -0.065 | -0.052 | -0.05 |
| % Growth | -7.4% | -25.4% | -3.8% | – |
| EPS Diluted | -0.07 | -0.065 | -0.052 | -0.05 |
| Weighted Avg Shares Out | 129,171 | 129,170 | 129,170 | 126,621 |
| Weighted Avg Shares Out Dil | 129,171 | 129,170 | 129,170 | 126,621 |
| Supplemental Information | – | – | – | – |
| Interest Income | $570 | $645 | $720 | $837 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $4 | $4 | $4 |
| EBITDA | -$8,688 | -$9,036 | -$7,410 | -$7,147 |
| % Margin | – | – | – | – |